LIPIDIL

This brand name is authorized in Australia, Brazil, Canada, Cyprus, Ecuador, Germany, Japan, Mexico.

Active ingredients

The drug LIPIDIL contains one active pharmaceutical ingredient (API):

1	Fenofibrate UNII U202363UOS - FENOFIBRATE
	Fenofibrate is a fibric acid derivative whose lipid modifying effects reported in humans are mediated via activation of Peroxisome Proliferator Activated Receptor type α (PPARα). Through activation of PPARα, fenofibrate increases lipolysis and elimination of atherogenic triglyceride rich particles from plasma by activating lipoprotein lipase and reducing production of Apoprotein C-III.
	Read more about Fenofibrate

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LIPIDIL NT Film coated tablet	MPI, EU: SmPC	Υπουργείο Υγείας (CY)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C10AB05	Fenofibrate	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AB Fibrates
Discover more medicines within C10AB05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	9022W, 9023X, 9246P, 9247Q
BR	Câmara de Regulação do Mercado de Medicamentos	500214090032117, 500214090032217, 500220060045607, 500220090046307
CA	Health Products and Food Branch	02241602, 02269074, 02269082
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	04031397, 04031405
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	360970612
JP	医薬品医療機器総合機構	2183006F3023, 2183006F4020
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	349M98